ALTIMMUNE, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ALTIMMUNE, INC. (ALT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- ALTIMMUNE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.79M, a 21.82% decline year-over-year.
- ALTIMMUNE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.38M, a 15.87% decline year-over-year.
- ALTIMMUNE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.55M, a 15.46% increase year-over-year.
- ALTIMMUNE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.57M, a 17.28% decline year-over-year.
- ALTIMMUNE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $16.08M, a 11.69% increase from fiscal 2024.
- ALTIMMUNE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $14.39M, a 35.27% increase from fiscal 2023.
- ALTIMMUNE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $10.64M, a 31.34% increase from fiscal 2022.
- ALTIMMUNE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $8.10M, a 46.78% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.79M 10-Q · filed 2026-08-12 | $6.17M derived: sum of 2 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $3.38M 10-Q · filed 2026-08-12 | |||||
| 2025-12-31 | $16.08M 10-K · filed 2026-03-06 | |||||
| 2025-09-30 | $3.55M 10-Q · filed 2025-11-06 | $7.12M derived: sum of 2 quarters · filed 2026-08-12 | $11.13M derived: sum of 3 quarters · filed 2026-08-12 | |||
| 2025-06-30 | $3.57M 10-Q · filed 2026-08-12 | $7.58M derived: sum of 2 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $4.01M 10-Q · filed 2026-08-12 | |||||
| 2024-12-31 | $14.39M 10-K · filed 2026-03-06 | |||||
| 2024-09-30 | $3.08M 10-Q · filed 2025-11-06 | $7.39M derived: sum of 2 quarters · filed 2025-11-06 | $11.04M derived: sum of 3 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $4.31M 10-Q · filed 2025-11-06 | $7.96M derived: sum of 2 quarters · filed 2025-11-06 | ||||
| 2024-03-31 | $3.65M 10-Q · filed 2025-11-06 | |||||
| 2023-12-31 | $10.64M 10-K · filed 2025-02-27 | |||||
| 2023-09-30 | $2.71M 10-Q · filed 2024-11-12 | $5.50M derived: sum of 2 quarters · filed 2024-11-12 | $8.17M derived: sum of 3 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $2.79M 10-Q · filed 2024-11-12 | $5.46M derived: sum of 2 quarters · filed 2024-11-12 | ||||
| 2023-03-31 | $2.67M 10-Q · filed 2024-11-12 | |||||
| 2022-12-31 | $8.10M 10-K · filed 2024-03-27 | |||||
| 2022-09-30 | $2.13M 10-Q · filed 2023-11-07 | $4.18M derived: sum of 2 quarters · filed 2023-11-07 | $6.21M derived: sum of 3 quarters · filed 2023-11-07 | |||
| 2022-06-30 | $2.05M 10-Q · filed 2023-11-07 | $4.08M derived: sum of 2 quarters · filed 2023-11-07 | ||||
| 2022-03-31 | $2.03M 10-Q · filed 2023-11-07 | |||||
| 2021-12-31 | $5.52M 10-K · filed 2023-02-28 | $5.52M 10-K · filed 2022-03-15 | ||||
| 2021-09-30 | $1.50M 10-Q · filed 2022-11-10 | $1.50M 10-Q · filed 2021-11-09 | $2.98M derived: sum of 2 quarters · filed 2022-11-10 | $4.20M derived: sum of 3 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $1.49M 10-Q · filed 2022-11-10 | $1.48M 10-Q · filed 2021-08-10 | $2.70M derived: sum of 2 quarters · filed 2022-11-10 | |||
| 2021-03-31 | $1.22M 10-Q · filed 2022-11-10 | $1.22M 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | $2.58M 10-K · filed 2022-03-15 | |||||
| 2020-09-30 | $1.32M 10-Q · filed 2021-11-09 | $1.65M derived: sum of 2 quarters · filed 2021-11-09 | $1.87M derived: sum of 3 quarters · filed 2021-11-09 | |||
| 2020-06-30 | $330.51K 10-Q · filed 2021-11-09 | $545.43K derived: sum of 2 quarters · filed 2021-11-09 | ||||
| 2020-03-31 | $214.92K 10-Q · filed 2021-11-09 | |||||
| 2019-12-31 | $1.26M 10-K · filed 2021-02-25 | |||||
| 2019-09-30 | $287.77K 10-Q · filed 2020-11-09 | $577.55K derived: sum of 2 quarters · filed 2020-11-09 | $985.26K derived: sum of 3 quarters · filed 2020-11-09 | $1.02M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $289.77K 10-Q · filed 2020-11-09 | $697.49K derived: sum of 2 quarters · filed 2020-11-09 | $737.20K derived: sum of 3 quarters · filed 2020-11-09 | $836.09K derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $407.71K 10-Q · filed 2020-11-09 | $447.43K derived: sum of 2 quarters · filed 2020-11-09 | $546.32K derived: sum of 3 quarters · filed 2020-11-09 | $806.09K derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2018-12-31 | $39.71K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $138.60K derived: sum of 2 quarters · filed 2020-03-27 | $398.37K derived: sum of 3 quarters · filed 2020-03-27 | $762.16K 10-K · filed 2020-03-27 | ||
| 2018-09-30 | $98.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $358.66K derived: sum of 2 quarters · filed 2018-11-13 | $722.45K 10-Q · filed 2018-11-13 | $1.03M derived: sum of 4 quarters · filed 2019-04-01 | ||
| 2018-06-30 | $259.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $623.56K 10-Q · filed 2018-08-14 | $928.83K derived: sum of 3 quarters · filed 2019-04-01 | |||
| 2018-03-31 | $363.79K 10-Q · filed 2018-05-15 | $669.06K derived: sum of 2 quarters · filed 2019-04-01 | ||||
| 2017-12-31 | $305.27K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $1.21M 10-K · filed 2019-04-01 | ||||
| 2017-09-30 | $905.23K 10-Q · filed 2017-11-09 | |||||
| 2017-03-31 | $197.13K 10-Q · filed 2018-05-15 | |||||
| 2016-12-31 | $794.58K 10-K · filed 2018-04-02 | $2.24M 10-K · filed 2017-03-14 | ||||
| 2015-12-31 | $613.02K 10-K · filed 2017-03-14 | |||||
| 2014-12-31 | $1.65M 10-K · filed 2017-03-14 | |||||
| 2013-12-31 | $1.35M 10-K · filed 2016-03-11 | |||||
| 2012-12-31 | $1.80M 10-K · filed 2015-03-11 | |||||
| 2011-12-31 | $2.25M 10-K · filed 2014-03-11 | |||||
| 2010-12-31 | $2.29M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |